参考文献/References:
[1] Anker SD,Coats AJ.Cardiac cachexia:a syndrome with impaired survival and immune and neuroendocrine activation[J].Chest,1999,115(3):836-847.
[2] von Haehling S, Lainscak M, Springer J,et al. Cardiac cachexia:a systematic overview [J].Pharmacol Ther,2009,121(3):227-252.
[3] Sandek A, Bauditz J, Swidsinski A, et al. Altered intestinal function in patients with chronic heart failure[J]. J Am Coll Cardiol,2007,50(16):1561-1569.
[4] Arutyunov GP, Kostyukevich OI, Serov RA, et al. Collagen accumulation and dysfunctional mucosal barrier of the small intestine in patients with chronic heart failure[J].Int J Cardiol,2008,125(2):240-245.
[5] Sandek A,Swidsinski A,Schroedl W,et al. Intestinal blood flow in patients with chronic heart failure:a link with bacterial growth, gastrointestinal symptoms,and cachexia[J].J Am Coll Cardiol,2014,64(11):1092-1102.
[6] Yoshida T, Tabony AM, Galvez S, et al. Molecular mechanisms and signaling pathways of angiotensin Ⅱ-induced muscle wasting: potential therapeutic targets for cardiac cachexia[J]. Int J Biochem Cell Biol,2013,45(10):2322-2332.
[7] Schulze PC. Protein catabolism and impairment of skeletal muscle insulin signalling in heart failure[J]. Clin Sci(Lond),2010,119(11):465-466.
[8] Isgaard J, Bergh CH, Caidahl K, et al. A placebo-controlled study of growth hormone in patients with congestive heart failure[J].Eur Heart J, 1998,19(11):1704-1711.
[9] Swan JW, Anker SD, Walton C, et al. Insulin resistance in chronic heart failure:relation to severity and etiology of heart failure[J].J Am Coll Cardiol, 1997,30(2):527-532.
[10] Donehner W,Gathercole D,Cicoira M,et al. Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure[J].J Am Coll Cardiol,2005,46(6):1019-1026.
[11] Marina PO,Romeiro FG,Paiva SA,et al. Heart failure-induced cachexia[J].Arq Bras Cardiol,2013,100(5):476-482.
[12] Levine B, Kalman J, Mayer L, et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure[J]. N Engl J Med, 1990,323(4):236-241.
[13] Torre-Amione G,Kapadia S,Benedict C,et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction(SOLVD)[J]. J Am Coll Cardiol,1996,27(5):1201-1206.
[14] Deswal A,Petersen NJ,Feldman AM,et al. Cytokines and cytokine receptors in advanced heart failure:an analysis of the cytokine database from the Vesnarinone trial(VEST)[J].Circulation,2001,103(16):2055-2059.
[15] Tracey KJ, Morgello S, Koplin B, et al. Metabolic effects of cachectin/tumor necrosis factor are modified by site of production[J].J Clin Invest,1990,86(6):2014-2024.
[16] von Haehling S, Schefold JC, Lainscak M, et al. Inflammatory biomarkers in heart failure revisited:much more than innocent bystanders [J].Heart Fail Clin,2009,5(4):549-560.
[17] Yndestad A, Damas JK, Oie E,et al. Systemic inflammation in heart failure:the whys and wherefores[J].Heart Fail Rev, 2006,11(1):83-92.
[18] Anker SD, Egerer KR, Volk HD, et al. Elevated soluble CD14 receptors and altered cytokines in chronic heart failure[J].Am J Cardiol,1997,79(10):1426-1430.
[19] von Haehling S, Genth-Zotz S, Anker SD, et al. Cachexia:a therapeutic approach beyond cytokine antagonism[J].Int J Cardiol,2002,85(1):173-183.
[20] Chatterjee K. Neurohormonal activation in congestive heart failure and the role of vasopressin[J].Am J Cardiol, 2005,95(9A):8B-13B.
[21] Anker SD, Ponikowski PP, Clark AL, et al. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure[J].Eur Heart J, 1999,20(9):683-693.
[22] von Haehling S, Doehner W, Anker SD. Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure[J].Cardiovasc Res,2007,73(2):298-309.
[23] Brasier AR, Recinos A 3rd, Eledrisi MS. Vascular inflammation and the renin-angiotensin system[J].Arterioscler Thromb Vasc Biol,2002,22(8):1257-1266.
[24] Anand IS, Florea VG. Traditional and novel approaches to management of heart failure:successes and failures[J].Cardiol Clin, 2008,26(1):59-72.
[25] Du Bois P,Pablo Tortola C, Lodka D,et al. Angiotensin Ⅱ induces skeletal muscle atrophy by activating TFEB-mediated MuRF1 expression[J].Circ Res, 2015,117(5):424-436.
[26] Yoshida T, Delafontaine P. Mechanisms of cachexia in chronic disease states[J].J Med Sci,2015,350(4):250-256.
[27] Anker SD, Negassa A, Coats AJ, et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors:an observational study[J]. Lancet,2003,361(9363):1077-1083.
[28] Boxall BW, Clark AL. Beta-blockers and weight change in patients with chronic heart failure[J].J Card Fail,2012,18(3):233-237.
相似文献/References:
[1]丁娟,刘地川.心力衰竭与线粒体功能障碍的研究进展[J].心血管病学进展,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(3):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
[2]罗秀林,综述,张烁,等.肾动脉去交感神经术治疗心力衰竭——希望还是炒作[J].心血管病学进展,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
[3]李慧,综述,齐国先,等.老年射血分数保留的心功能不全研究进展[J].心血管病学进展,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
LI Hui,QI Guoxian.Research Progress of Heart Failure with Preserved Ejection Fraction in Elderly People[J].Advances in Cardiovascular Diseases,2016,(3):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
[4]亢玉,综述,张庆,等.二尖瓣瓣叶在功能性二尖瓣反流发生机制中的角色[J].心血管病学进展,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(3):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
[5]史秀莉,张庆,喻鹏铭.心力衰竭患者运动训练方式及其疗效的研究进展[J].心血管病学进展,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on
Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(3):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
[6]熊卓超,陈康玉,严激.无创血流动力学评价在心力衰竭中的应用进展[J].心血管病学进展,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(3):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[7]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(3):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[8]何燕 刘育.C型利钠肽与心力衰竭[J].心血管病学进展,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
HE Yan,LIU Yu.C-type Natriuretic Peptide and Heart Failure[J].Advances in Cardiovascular Diseases,2019,(3):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
[9]吴彤 高东来.心房颤动合并心力衰竭的射频消融治疗[J].心血管病学进展,2019,(5):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
WU TongGAO Donglai.Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2019,(3):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
[10]方砚 王效浣 郭朝霞.血流介导性血管扩张评价心血管病患者肱动脉内皮功能的研究进展[J].心血管病学进展,2019,(5):793.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.032]
FANG Yan,WANG Xiaohuan,GUO Zhaoxia.Flow- mediated Vasodilation Evaluation of Brachial Artery Endothelial Function in Patients with Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(3):793.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.032]